argenex (NASDAQ:ARGX) Price Target Raised to $880.00

argenex (NASDAQ:ARGX) had its price target hoisted by Wedbush from $800.00 to $880.00 in a research report report published on Monday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock. Wedbush also issued estimates for argenex’s Q3 2025 earnings at $4.46 EPS, Q4 2025 earnings at $5.05 EPS, Q1 2026 earnings at $5.51 EPS, Q2 2026 earnings at $6.18 EPS, Q3 2026 earnings at $6.73 EPS, Q4 2026 earnings at $7.31 EPS, FY2026 earnings at $25.75 EPS, FY2027 earnings at $37.12 EPS and FY2028 earnings at $54.68 EPS.

A number of other brokerages also recently issued reports on ARGX. Stifel Nicolaus set a $882.00 price objective on shares of argenex in a research note on Thursday, September 18th. Wells Fargo & Company increased their price target on shares of argenex from $741.00 to $756.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Jefferies Financial Group set a $818.00 price objective on shares of argenex and gave the company a “buy” rating in a research note on Tuesday, August 26th. Truist Financial upped their target price on argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Finally, Royal Bank Of Canada assumed coverage on argenex in a report on Monday, August 25th. They issued an “outperform” rating and a $850.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $817.53.

argenex Stock Performance

NASDAQ:ARGX opened at $815.61 on Monday. argenex has a 52 week low of $510.05 and a 52 week high of $819.71. The firm’s 50-day simple moving average is $727.75 and its 200 day simple moving average is $632.02. The firm has a market cap of $49.92 billion, a price-to-earnings ratio of 41.83, a P/E/G ratio of 0.87 and a beta of 0.46.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.90. The firm had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. Sell-side analysts anticipate that argenex will post 3.13 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ARGX. Rakuten Securities Inc. lifted its stake in shares of argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company’s stock valued at $36,000 after acquiring an additional 22 shares during the last quarter. WPG Advisers LLC bought a new stake in argenex during the 1st quarter worth $37,000. Golden State Wealth Management LLC acquired a new position in argenex in the 1st quarter worth about $44,000. Brooklyn Investment Group raised its position in argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 38 shares during the last quarter. Finally, MAI Capital Management boosted its stake in shares of argenex by 866.7% during the second quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after purchasing an additional 78 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.